



June 26, 2018

Dear Colleague,

We are pleased to announce that we have added Dynavax's Heplisav-B vaccine (adult Hepatitis B) to the Atlantic portfolio. There is no cure for Hepatitis B, and effective vaccination is critical to reducing the spread of this disease.

Dynavax recently launched Heplisav-B, and this vaccine offers a number of advantages:

- Heplisav-B is the only 2-dose series adult Hepatitis B vaccine; dosing can be completed over one month
- Higher levels of immunity are provided for patients 18 to 70 years of age and is approved to be given to adults 18 and older
- Higher rate of protective immunity for diabetic adults – the CDC recommends Hepatitis B vaccination for diabetics aged 19 – 59
- Heplisav-B is in stock and ready for order, and comes in a 5 individual-dose presentation

Heplisav-B is not sold directly by Dynavax, and can be purchased from a limited number of authorized distributors. The lowest Atlantic final price of \$98.93 per dose (which includes Federal Excise Tax and prompt pay and online order discounts) can be obtained from VaccineShoppe or VaxServe. The CPT code is 90739, and as with any new vaccine we recommend you confirm reimbursement with your key payers.

You can obtain additional clinical and product information about Heplisav-B at www.dynavax.com or by calling 1-844-375-4728. Using Heplisav-B does not impact compliance requirements to use Merck's adult Hepatitis B vaccine Recombivax.

Please contact us if you need any additional information and we are confident Heplisav-B can support your adult Hepatitis B immunization needs.

Sincerely,

Jeff Winokur
President
jwinokur@atlanticehealthpartners.com